Anticholinergics for overactive bladder therapy: central nervous system effects.
about
Assessment of cognitive safety in clinical drug developmentCost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.Anticholinergic burden and cognitive function in a large German cohort of hospitalized geriatric patients.Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects.Long-term cognitive and functional effects of potentially inappropriate medications in older women.Evaluation of Overactive Bladder in Male Antidepressant Users: A Prospective Study.Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.Oxybutynin: past, present, and future.Cardiovascular effects of antimuscarinic agents in overactive bladder.What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder?Is overactive bladder a brain disease? The pathophysiological role of cerebral white matter in the elderly.Important drug–drug interactions for treatments that target overactive bladder syndrome.A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders.The effects of antimuscarinic treatment on the cognition of spinal cord injured individuals with neurogenic lower urinary tract dysfunction: a prospective controlled before-and-after study.Urinary incontinence in men: current and developing therapy options.Assessment of overactive bladder in women antidepressant users.Cholinergic muscarinic receptors: new opportunities to treat psychiatric disorders.Imidafenacin has no influence on learning in nucleus basalis of Meynert-lesioned rats.Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage.Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines?No Increased Risk of Fracture in Patients Receiving Antimuscarinics for Overactive Bladder Syndrome: A Retrospective Cohort Study.Influence of antimuscarinic therapy on cognitive functions and quality of life in geriatric patients treated for overactive bladder.Tolterodine activates the prefrontal cortex during bladder filling in OAB patients: a real-time NIRS-urodynamics study.Differential Prescribing of Antimuscarinic Agents in Older Adults with Cognitive Impairment.Influence of the Short-term Intake of High Doses of Solifenacin and Trospium on Cognitive Function and Health-Related Quality of Life in Older Women With Urinary Incontinence.
P2860
Q28084637-F37BFD1A-59C1-4449-B9F1-8BC6A1214CCBQ33696642-0FFB137D-A3EC-4B13-AF24-000770E12C56Q36277027-72749ABA-9B8E-48B7-B5B0-1801ED2A70EDQ37399563-A1421934-AE4E-4E96-A551-ABDBA492994DQ37670854-68A67F0A-16EC-45D8-A1A5-F33E8E4BE241Q37737694-CFB38E14-A57F-472E-AFF0-408FB55D786EQ38032608-7B7B1635-7EB8-465D-8348-8A90B907EEACQ38043396-52656B8A-9468-436C-8D48-3E3D82947EB2Q38116972-95CAFE98-CCB7-4D31-AF05-AEE5A81DBD8BQ38127144-FB6D53D1-6401-4F8E-990F-A017EA843E31Q38151888-E61FFC45-17FA-4514-9D64-63C61B33E917Q38162704-F45D8B4A-0879-400E-A33E-4D3D5B176E8BQ38391474-99B6F038-6859-49FC-9E21-2FEFDAA84AB0Q38635232-ACA343BE-3EF3-4BBA-AAD1-80EA200B3F07Q38708104-E40FF3D5-525D-4BA4-949D-6C2987B784F8Q40656507-5059FD1A-9FBE-4D5C-80F7-D6932C771C71Q44141796-46F081A0-EE72-48C2-BFE6-8D5B60B5C975Q45408584-D04A1380-3F87-46B1-8C62-A9F87913AB66Q46573653-AE85BAD9-F0F1-4417-8CB1-E5CB3F71FA71Q47117943-35E99740-F9FA-4BF6-8EA2-75E28273E131Q47189750-38410E91-CA04-4464-96C5-B3A901F421C8Q48054495-B0418A1E-BFD1-47B8-8D67-2B5EED1AA825Q49030093-02A467DF-8D30-4C99-B743-FF4FBB771A83Q50533611-A0E1ED75-2916-41D9-A2B8-1F96D28DA4E5Q53699301-3F8FBB36-EAB3-4425-8894-245DBF50A43A
P2860
Anticholinergics for overactive bladder therapy: central nervous system effects.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Anticholinergics for overactive bladder therapy: central nervous system effects.
@en
Anticholinergics for overactive bladder therapy: central nervous system effects.
@nl
type
label
Anticholinergics for overactive bladder therapy: central nervous system effects.
@en
Anticholinergics for overactive bladder therapy: central nervous system effects.
@nl
prefLabel
Anticholinergics for overactive bladder therapy: central nervous system effects.
@en
Anticholinergics for overactive bladder therapy: central nervous system effects.
@nl
P2860
P1476
Anticholinergics for overactive bladder therapy: central nervous system effects
@en
P2093
Michael Chancellor
Timothy Boone
P2860
P304
P356
10.1111/J.1755-5949.2011.00248.X
P577
2011-02-16T00:00:00Z